Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TTC-352 |
| Synonyms | |
| Therapy Description |
TTC-352 is a partial estrogen receptor agonist that inhibits growth of ER-positive cancer cells (PMID: 25205655, PMID: 32696319). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TTC-352 | TTC 352 | TTC-352 is a partial estrogen receptor agonist that inhibits growth of ER-positive cancer cells (PMID: 25205655, PMID: 32696319). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03201913 | Phase I | TTC-352 | Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy | Completed | USA | 0 |